• 1Q24 Daxxify sales were $22.1M, -8% QoQ — due to $2.0M of redeemed coupons and normal seasonality in the aesthetics business — and +44% YoY.
• 1Q24 Daxxify volume (units shipped) was +7% QoQ.
• 1Q24 dermal-filler sales were 29.6M, -14% QoQ and -2% YoY.
• Cash at 3/31/24 was $277.1M, a $23.2M increase relative to 12/30/23 due to $94.0M of net proceeds from the Mar 2024 public offering.
• 1Q24 non-GAAP operating expenses (excluding COGS) were $68.9M, slightly below the quarterly run rate for RVNC’s full-year 2024 guidance of $290-310M.
2024 guidance
• RVNC re-iterated 2024 guidance for product revenue (Daxxify + RHA) of >=$280M.
• RVNC re-iterated 2024 guidance for non-GAAP operating expenses of $290-310M.